Aventis Overview
- Year Founded
-
1979
- Status
-
Acquired/Merged
- Employees
-
75,567
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
11
Aventis General Information
Description
Developer of pharmaceuticals and vaccines for preventative medicine.
Contact Information
Website
www.aventis.comCorporate Office
- 16 avenue de l'Europe
- 67300 Schiltigheim
- France
Corporate Office
- 16 avenue de l'Europe
- 67300 Schiltigheim
- France
Aventis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aventis Patents
Aventis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026050706-A1 | Nk cells having reduced cd38 expression and method for producing | Pending | 30-Aug-2024 | ||
| US-20250034129-A1 | Crystalline forms of (6s,7s)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2h-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione | Pending | 28-Jul-2023 | ||
| US-20100151463-A1 | Method for determining the likelihood of response to her2 inhibitors | Inactive | 05-Sep-2008 | ||
| EP-2294215-A1 | Tests to predict responsiveness of cancer patients to chemotherapy treatment options | Active | 12-May-2008 | ||
| EP-2294215-A4 | Tests to predict responsiveness of cancer patients to chemotherapy treatment options | Active | 12-May-2008 | C12Q1/6886 |
Aventis Signals
Aventis Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aventis Investments (11)
Aventis’s most recent deal was a Later Stage VC with Scynexis for . The deal was made on 27-Mar-2008.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Scynexis | 27-Mar-2008 | Later Stage VC | Drug Discovery | ||
| Nereus Pharmaceuticals | 06-Mar-2006 | Later Stage VC | Drug Discovery | ||
| Scynexis | 13-Feb-2006 | Later Stage VC | Drug Discovery | ||
| Amphora Discovery | 08-Dec-2004 | Later Stage VC | Drug Discovery | ||
| Targacept | 06-Dec-2004 | Later Stage VC | Biotechnology |
Aventis Exits (11)
Aventis’s most recent exit was on 27-Mar-2008 from Scynexis. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Scynexis | 27-Mar-2008 | Completed |
|
||
| Nereus Pharmaceuticals | 06-Mar-2006 | Completed |
|
||
| Scynexis | 13-Feb-2006 | Completed |
|
||
| Amphora Discovery | 08-Dec-2004 | Completed |
|
||
| Targacept | 06-Dec-2004 | Later Stage VC | Completed |
|
Aventis FAQs
-
When was Aventis founded?
Aventis was founded in 1979.
-
Where is Aventis headquartered?
Aventis is headquartered in Schiltigheim, France.
-
What is the size of Aventis?
Aventis has 75,567 total employees.
-
What industry is Aventis in?
Aventis’s primary industry is Pharmaceuticals.
-
Is Aventis a private or public company?
Aventis is a Private company.
-
What is the current valuation of Aventis?
The current valuation of Aventis is .
-
What is Aventis’s current revenue?
The current revenue for Aventis is .
-
Who are Aventis’s investors?
HCRx and Paul Capital Partners have invested in Aventis.
-
When was Aventis acquired?
Aventis was acquired on 12-Aug-2004.
-
Who acquired Aventis?
Aventis was acquired by Sanofi-Synthelabo.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process